29th January 2019 – Pioneering publication concludes that patients presenting evidence of sepsis and receiving continuous monitoring with the Sensium® patch were administered antibiotics six hours faster
Abingdon (UK) 29th January 2019 - Sensium®, a leading global brand in early detection of patient deterioration, announces the availability of a pioneering publication demonstrating the benefits of continuous wireless vital signs monitoring.
In this interview, the Lead Author of the study, Candice Downey and Ron Daniels, CEO of the UK Sepsis Trust discuss the clinical need for remote monitoring with Sensium® and results and significance of the recent publication.
The results of a randomized control trial (RCT), undertaken within two surgical wards at the St James’s University Hospital, Leeds, has been published in the Journal of Medical Internet Research1. Patients in the study received either continuous monitoring by a wireless patch (Sensium®) and intermittent vital signs monitoring, or intermittent monitoring alone. The study’s primary outcome measure was time to administration of antibiotics in patients who showed evidence of sepsis. The study recruited 350 patients (January - June 2017), 140 patients received continuous remote monitoring and 210 received intermittent monitoring alone.
Although the results of the study were not statistically significant, they showed that patients receiving remote continuous vital signs monitoring with the Sensium® patch were:
• Administered antibiotics on average 6 hours faster after evidence of sepsis
• Had a 10% shorter average length of hospital stay
• Were on average 45% less likely to require readmission within 30 days of discharge
Alison Burdett, Sensium Chief Scientific Officer stated about the publication:
‘’Sensium® consider independent clinical validation of our technology as extremely important. We are delighted to see the results of this study which, as far as we are aware, is the first peer-reviewed publication to show a clinical benefit from a wearable patch-based device for continuous vital signs monitoring.’’
Candice Downey, Lead Author of the publication stated about the findings:
“Although this is early research, our study has shown that continuous monitoring is possible in the hospital setting, and there is evidence of potential benefit in surgical patients. We’ve used these findings to design the next stage of the research, with the aim of making surgery safer in the future.”
Professor David Jayne, Chief Investigator of the study stated about the publication:
“Remote patient monitoring has benefits for patients, clinicians and healthcare providers. In the future it is likely that all patients undergoing major surgery will be monitored in this way.”
Ron Daniels, CEO of the UK Sepsis Trust and Global Sepsis Alliance and Clinical Adviser to WHO stated about the findings:
“Any system which provides earlier indications of patient deterioration than can be achieved with manual monitoring alone, could prove invaluable in the global fight against Sepsis. Not only might such systems deliver targeted notifications at the first signs of sepsis allowing much earlier treatment, but they will also allow the real time monitoring of patients' responses to treatment.
The recent RCT in Leeds has demonstrated the potential of such early warning systems, with patients in the Sensium group being treated on average 6 hours quicker than the control group in the presence of sepsis. Anything that can be done to more quickly identify and treat sepsis has to be a good thing and will lead to lives saved.”
Sensium® is the only end-to-end system designed and optimised exclusively for ambulatory patients, enabling early detection of deterioration of mobile patients in general medical and surgical wards. Sensium® is a discreet, wearable, wireless system for monitoring vital signs of patients outside of high acuity areas. By notifying clinicians of changes in patients’ vital signs, Sensium® brings the nurse to the deteriorating patient.
Currently 75% of all adverse events and preventable deaths occur outside the ICU in unmonitored beds. Sensium® allows unmonitored beds to be easily and affordably converted to monitored beds to ensure that these adverse events and preventable patients deaths are minimised.
The system received FDA 510(k) clearance in 2011 and the CE Mark in 2013.
The key benefit of Sensium® is that it provides vital signs data between routine observation rounds which are typically conducted every four to eight hours. The system enables earlier detection of patient deterioration and allows nursing staff to intervene much more quickly - thereby improving patient care, shortening hospital stays and reducing healthcare costs.
The system is based on SENSIUM's proprietary ultra-low power technologies. As a result, the Sensium® System is the only lightweight wearable system which has a six-day battery life and is capable of monitoring freely ambulatory patients.
Sensium® was developed over several years by world-renowned digital healthcare experts, including Professor Toumazou, Regius Professor of Engineering and founding director of the Institute of Biomedical Engineering at Imperial College. Sensium® is a registered trade mark of Sensium Healthcare Ltd
For further information, please contact:
Tel: +44 1235 438 950 Email: firstname.lastname@example.org
115 Olympic Avenue,
OX14 4SA, UK